Senshio
- Prescription status not stated
- Urinary and reproductive system, hormones
- Active substance
- Ospemifene
- Made by
- Shionogi B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (Osphena). It describes the substance, not this exact product.
OSPHENA is an estrogen receptor agonist/antagonist with tissue selective effects.
Its biological actions are mediated through binding to estrogen receptors.
In vitro experiments with human liver microsomes indicated that ospemifene primarily undergoes metabolism via CYP3A4, CYP2C9, and CYP2C19.
Following an oral administration of ospemifene, approximately 75% and 7% of the dose were excreted in feces and urine, respectively.
After a single oral administration of OSPHENA 60 mg tablet in postmenopausal women with a high fat/high calorie (860 kcal) meal, C max was reached at approximately 2.5 hours (range: 1 to 6 hours) post-dose.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-02-14
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Shionogi B.V. |
|---|---|
| Active substance | Ospemifene |
| Used in | Urinary and reproductive system, hormones |
| Classification | G03XC05 · Urinary and reproductive system, hormones |
| Authorised on | 2015-01-14 |
| Last updated by the regulator | 2024-11-25 |
| EMA product number | EMEA/H/C/002780 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).